<p>A-B, HepG2 and Huh7 cells were exposed to 100 nM bufalin and/or 5 μM of sorafenib in the presence or absence of perifosine (10 μM) for 48 h. (A) Cell viability (%) was then compared with the corresponding untreated cells. (B) The percentages of apoptotic cells (%) were measured by flow cytometry. Untransfected cells served as controls. C-D, HepG2 and Huh7 cells were transfected with control or Akt siRNA for 24 h and then incubated with 100 nM bufalin, 5 μM sorafenib, or a combination of the two drugs for 24 h. (C) Cell viability (%) was compared with control siRNA-transfected cells. (D) The percentages of apoptotic cells (%) were measured by flow cytometry. Untransfected cells served as controls. The data represent three independent expe...
BACKGROUND: Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This stu...
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, ...
Purpose. Tumor microenvironment confers drug resistance to kinase inhibitors by increasing RKT ligan...
<p>(A) Huh7 and Huh7-Sora cells were cultured in complete medium, and the viability was examined aft...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<div><p>The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib...
<p>(A) After pretreatment with 10 µM Stattic or DMSO for 20 min, HaCaT cells were incubated in mediu...
<p>(A) HepG2 and Huh7 cells were exposed to different concentrations of bufalin and/or sorafenib for...
<p>a) Caspase 3/7 activity was evaluated in ACHN cells treated with Sorafenib for 24 hours. b) Viabi...
<p>a) ACHN and 786-O cells were treated for 48 h at the indicated concentrations of Sorafenib and vi...
The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigate...
Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mech...
Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular...
BACKGROUND: Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This stu...
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, ...
Purpose. Tumor microenvironment confers drug resistance to kinase inhibitors by increasing RKT ligan...
<p>(A) Huh7 and Huh7-Sora cells were cultured in complete medium, and the viability was examined aft...
<p>Following incubation with increasing doses of sorafenib, viable cell counts and apoptotic cell de...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were in...
<div><p>The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib...
<p>(A) After pretreatment with 10 µM Stattic or DMSO for 20 min, HaCaT cells were incubated in mediu...
<p>(A) HepG2 and Huh7 cells were exposed to different concentrations of bufalin and/or sorafenib for...
<p>a) Caspase 3/7 activity was evaluated in ACHN cells treated with Sorafenib for 24 hours. b) Viabi...
<p>a) ACHN and 786-O cells were treated for 48 h at the indicated concentrations of Sorafenib and vi...
The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigate...
Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mech...
Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular...
BACKGROUND: Sorafenib is a multi-kinase inhibitor used in the treatment of various cancers. This stu...
Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, ...
Purpose. Tumor microenvironment confers drug resistance to kinase inhibitors by increasing RKT ligan...